Atomoxetine
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2002
- First approval year
- 2002
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Atomoxetine
- Molecular weight
- 255.36
- Structure (SMILES)
- CNCC[C@@H](Oc1ccccc1C)c1ccccc1
- atomoxetine component of ad 109
- atomoxetine component of ad 313
- Atomoxetine component of ad-109
- Atomoxetine component of ad-313
- atomoxetine component of ad109
- Atomoxetine component of ad109
- atomoxetine component of ad313
- Atomoxetine component of ad313
- ad 109 component atomoxetine
- ad 313 component atomoxetine
- AD-109 COMPONENT ATOMOXETINE
- AD-313 COMPONENT ATOMOXETINE
- ad109 component atomoxetine
- AD109 COMPONENT ATOMOXETINE
- ad313 component atomoxetine
- AD313 COMPONENT ATOMOXETINE
- atomoxetina
- Atomoxetina
- atomoxetine
- Atomoxetine
- ATOMOXETINE [HSDB]
- atomoxetine [INN]
- ATOMOXETINE [MI]
- ATOMOXETINE [VANDF]
- Atomoxetine [WHO-DD]
- atomoxetine hsdb
- atomoxetine inn
- atomoxetine mi
- atomoxetine vandf
- atomoxetine who dd
- ATC classification codes
- N06BA09
Sources for recorded values
- CAS registry numbers
- 83015-26-3
- ChEMBL ID
- CHEMBL641
- InChIKey
- VHGCDTVCOLNTBX-QGZVFWFLSA-N
- PubChem compound IDs
- 54841
- FDA ingredient codes (UNII)
- ASW034S0B8
- 38400
- 353103
- Applicant
- LILLY
- Approval date
- 26 Nov 2002
- Application number
- NDA021411
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- United States (FDA)
- Approved
- Pharmacology name
- atomoxetine
- Type
- Synthetic organic
- Drug name stem
- -oxetine
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- NET
- Gene symbol
- SLC6A2
- Protein identifier
- P23975
- Median affinity
- 8.69
- Affinity units
- pKd
- Primary target
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- SERT
- Gene symbol
- SLC6A4
- Protein identifier
- P31645
- Median affinity
- 8.05
- Affinity units
- pKd
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- DAT
- Gene symbol
- SLC6A3
- Protein identifier
- Q01959
- Median affinity
- 5.97
- Affinity units
- pKd
Open Targets mechanisms
- Mechanism
- Norepinephrine transporter inhibitor
- Action type
- Inhibitor
- Target
- Sodium-dependent noradrenaline transporter
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- SLC6A2
- Protein identifier
- P23975
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Cocaine-Related Disorders
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002610
- Subject identifier
- D019970
- Condition
- Autistic Disorder
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003758
- Subject identifier
- D001321
- Condition
- Tobacco Use Disorder
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003768
- Subject identifier
- D014029
- Condition
- Sleep Apnea Syndromes
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003877
- Subject identifier
- D012891
- Condition
- Attention Deficit Disorder with Hyperactivity
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003888
- Subject identifier
- D001289
- Condition
- Substance-Related Disorders
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003890
- Subject identifier
- D019966
- Condition
- Sleep Apnea, Obstructive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003918
- Subject identifier
- D020181
- Condition
- Amphetamine-Related Disorders
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004701
- Subject identifier
- D019969
- Condition
- Tourette Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004895
- Subject identifier
- D005879
- Condition
- Hypotension, Orthostatic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005252
- Subject identifier
- D007024
- Condition
- Opioid-Related Disorders
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005611
- Subject identifier
- D009293
- Condition
- Marijuana Abuse
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007191
- Subject identifier
- D002189
- Condition
- Orthostatic Intolerance
- Highest recorded phase
- 1
- Condition identifier
- EFO:1000645
- Subject identifier
- D054971
- Condition
- Phobia, Social
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001917
- Subject identifier
- D000072861
- Condition
- Syncope, Vasovagal
- Highest recorded phase
- 2
- Condition identifier
- HP:0012668
- Subject identifier
- D019462
- Condition
- Cognitive Dysfunction
- Highest recorded phase
- 2
- Condition identifier
- HP:0100543
- Subject identifier
- D060825
- Condition
- Substance-Related Disorders
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002491
- Subject identifier
- D019966
- Condition
- Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Schizophrenia
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005090
- Subject identifier
- D012559
- Condition
- Diabetes Mellitus, Type 1
- Highest recorded phase
- 0.5
- Condition identifier
- MONDO:0005147
- Subject identifier
- D003922
- Condition
- Parkinson Disease
- Highest recorded phase
- 0.5
- Condition identifier
- MONDO:0005180
- Subject identifier
- D010300
- Condition
- Alcoholism
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007079
- Subject identifier
- D000437
- Condition identifier
- EFO_0001072
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001074
- Condition identifier
- EFO_0002610
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003758
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003768
- Condition identifier
- EFO_0003877
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003888
- Condition identifier
- EFO_0003890
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003918
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004701
- Condition identifier
- EFO_0004895
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005252
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005611
- Highest recorded phase
- 2
- Condition identifier
- EFO_0007191
- Highest recorded phase
- 2
- Condition identifier
- EFO_0803536
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000645
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001917
- Condition identifier
- HP_0000752
- Condition identifier
- HP_0000822
- Highest recorded phase
- 2
- Condition identifier
- HP_0001288
- Highest recorded phase
- 1
- Condition identifier
- HP_0001297
- Highest recorded phase
- 2
- Condition identifier
- HP_0001513
- Highest recorded phase
- 2
- Condition identifier
- HP_0010865
- Highest recorded phase
- 3
- Condition identifier
- HP_0012668
- Highest recorded phase
- 2
- Condition identifier
- HP_0025267
- Highest recorded phase
- 1
And 37 more, listed on the interactive page.
- Warning
- Black Box Warning
- Country
- United States
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Country
- United States
- Event
- abnormal loss of weight
- Reports
- 3
- Reporting signal score
- 6.60814
- Event
- affect lability
- Reports
- 13
- Reporting signal score
- 37.0287
- Event
- aggression
- Reports
- 44
- Reporting signal score
- 122.812
- Event
- agitation
- Reports
- 14
- Reporting signal score
- 16.8366
- Event
- anger
- Reports
- 12
- Reporting signal score
- 26.9543
- Event
- anti-ganglioside antibody positive
- Reports
- 1
- Reporting signal score
- 7.86879
- Event
- anxiety
- Reports
- 41
- Reporting signal score
- 61.4022
- Event
- bacterial infection
- Reports
- 10
- Reporting signal score
- 24.9075
- Event
- bipolar i disorder
- Reports
- 3
- Reporting signal score
- 9.51023
- Event
- blepharospasm
- Reports
- 5
- Reporting signal score
- 15.761
- Event
- bruxism
- Reports
- 22
- Reporting signal score
- 96.9143
- Event
- choreoathetosis
- Reports
- 15
- Reporting signal score
- 78.349
- Event
- circulatory collapse
- Reports
- 5
- Reporting signal score
- 8.19073
- Event
- coma
- Reports
- 7
- Reporting signal score
- 6.94941
- Event
- congenital anomaly
- Reports
- 5
- Reporting signal score
- 12.458
- Event
- coordination abnormal
- Reports
- 21
- Reporting signal score
- 70.8373
- Event
- crying
- Reports
- 30
- Reporting signal score
- 94.2454
- Event
- decreased appetite
- Reports
- 24
- Reporting signal score
- 25.2802
- Event
- decreased eye contact
- Reports
- 21
- Reporting signal score
- 145.631
- Event
- depressed mood
- Reports
- 28
- Reporting signal score
- 73.9423
- Event
- depression
- Reports
- 28
- Reporting signal score
- 32.4755
- Event
- disturbance in attention
- Reports
- 6
- Reporting signal score
- 6.50891
- Event
- drooling
- Reports
- 4
- Reporting signal score
- 9.47805
- Event
- drug intolerance
- Reports
- 10
- Reporting signal score
- 6.52832
- Event
- dyskinesia
- Reports
- 26
- Reporting signal score
- 67.0837
And 68 more, listed on the interactive page.
- NCT00089869
- NCT00216281
- NCT00167297
- NCT00174226
- NCT00181740
- NCT00181766
- NCT00181948
- NCT00183391
- NCT00190684
- NCT00191035
- NCT00191295
- NCT00191516
- NCT00191542
- NCT00191633
- NCT00191737
- NCT00191880
- NCT00254462
- NCT00299234
- NCT00320528
- NCT00356070
- NCT00386581
- NCT00429091
- NCT00447278
- NCT00471354
- NCT00528697
And 56 more, listed on the interactive page.
- Dose
- 0.5 mg/kg increasing to 1.2 mg/kg
- Route
- Oral
- How often
- Once daily or divided doses in the morning and late afternoon/early evening
- Discontinue without tapering
- Do not exceed 1.4 mg/kg or 100 mg in children up to 70 kg
- Initiate after minimum 3 days
- Initiate at 40 mg and increase to 80 mg in over 70 kg or adults
- May be taken with or without food
- Hydrogen bond acceptors
- 2
- Hydrogen bond donors
- 1
- Polar surface area
- 21.26
- Calculated partition coefficient (ALogP)
- 3.72
- Calculated partition coefficient (XLogP)
- 3.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 6
- Heavy atoms
- 19
- Molecular formula
- C17H21NO
- Monoisotopic mass
- 255.162314293
- Natural product
- Yes
- Recorded assays
- 362
- Active assays
- 75
- Confirmatory
- Other
- Adrenergic Uptake Inhibitors
These details could not be displayed.
Related records
Trials (148)
- A Bioequivalence (BE) Study in Healthy Subjects
- A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia
- A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
- A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in Adults
- A Dose Response Effect of Atomoxetine to the Acute Effects of Alcohol
- A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
- A Gene by Medication Interaction to the Acute Effects of Alcohol
- A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder
- A Novel Pharmacological Therapy for Obstructive Sleep Apnea
- A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
- A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents
- A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
- A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents
- A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan
- A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
- A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
- A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors
- ADHD Medication and Predictors of Treatment Outcome
- Agonist Replacement Therapy for Cocaine Dependence
- An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease
Approved for (1)
- Attention deficit-hyperactivity disorder
In development for (33)
- Alcohol abuse Phase 2
- Alcohol dependence Phase 2
- Attention deficit hyperactivity disorder, inattentive type Phase 2
- Autism Phase 3
- Autism spectrum disorder Phase 3
- Cancer Phase 3
- Cannabis dependence Phase 2
- Cocaine abuse Phase 2
- Cocaine dependence Phase 1
- Drug dependence Phase 2
- Huntington disease Phase 2
- Hypertensive disorder Phase 2
- Methamphetamine dependence Phase 1
- Multiple sclerosis Phase 2
- Nicotine dependence Phase 1
- Obesity disorder Phase 2
- Obesity-hypoventilation syndrome Phase 2
- Obstructive sleep apnea syndrome Phase 2
- Opiate dependence Phase 2
- Oppositional defiant disorder Phase 3
Other linked conditions (6)
- Anorexia nervosa
- Chronic obstructive pulmonary disease
- Depressive disorder
- Major depressive disorder
- Morbid obesity
- Schizoaffective disorder